| MeSH term | MeSH ID | Detail |
|---|---|---|
| Metabolism, Inborn Errors | D008661 | 46 associated lipids |
| Hypercholesterolemia | D006937 | 91 associated lipids |
| Thrombosis | D013927 | 49 associated lipids |
| Hypertension, Pulmonary | D006976 | 32 associated lipids |
| Peritonitis | D010538 | 38 associated lipids |
| Hemorrhage | D006470 | 15 associated lipids |
| Proteinuria | D011507 | 30 associated lipids |
| Spasm | D013035 | 5 associated lipids |
| Lymphoma | D008223 | 18 associated lipids |
| Alzheimer Disease | D000544 | 76 associated lipids |
Platelet activating factor
Platelet activating factor is a lipid of Glycerophospholipids (GP) class. Platelet activating factor is associated with abnormalities such as Atherosclerosis, Acute cholecystitis without calculus, Cholecystitis, Colitis and Cholecystitis, Acute. The involved functions are known as Cell Survival, Metabolic Inhibition, lipid oxidation, Apoptosis and Oxidation. Platelet activating factor often locates in soluble, Cellular Membrane, Smooth muscle (tissue), Intima and Tissue specimen. The associated genes with Platelet activating factor are apolipoprotein A-I Milano, Homologous Gene, TSPO gene, HBEGF gene and SLC33A1 gene. The related lipids are Hydroxycholesterols, Liposomes, 25-hydroxycholesterol, Lysophosphatidylcholines and Lipopolysaccharides. The related experimental models are Knock-out, Mouse Model and Transgenic Model.
Cross Reference
Introduction
To understand associated biological information of Platelet activating factor, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
What diseases are associated with Platelet activating factor?
Platelet activating factor is suspected in Ischemia, Pleurisy, Atherosclerosis, Inflammatory disorder, Retinal Diseases, Diabetes and other diseases in descending order of the highest number of associated sentences.
Related references are mostly published in these journals:
| Disease | Cross reference | Weighted score | Related literature |
|---|
Loading... please refresh the page if content is not showing up.
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with Platelet activating factor
PubChem Associated disorders and diseases
What pathways are associated with Platelet activating factor
There are no associated biomedical information in the current reference collection.
PubChem Biomolecular Interactions and Pathways
Link to PubChem Biomolecular Interactions and PathwaysWhat cellular locations are associated with Platelet activating factor?
Visualization in cellular structure
Associated locations are in red color. Not associated locations are in black.
Related references are published most in these journals:
| Location | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What functions are associated with Platelet activating factor?
Related references are published most in these journals:
| Function | Cross reference | Weighted score | Related literatures |
|---|
What lipids are associated with Platelet activating factor?
Related references are published most in these journals:
| Lipid concept | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What genes are associated with Platelet activating factor?
Related references are published most in these journals:
| Gene | Cross reference | Weighted score | Related literatures |
|---|
What common seen animal models are associated with Platelet activating factor?
Knock-out
Knock-out are used in the study 'A cardioprotective role for platelet-activating factor through NOS-dependent S-nitrosylation.' (Leary PJ et al., 2008).
Mouse Model
Mouse Model are used in the study 'A regulatory role of LPCAT1 in the synthesis of inflammatory lipids, PAF and LPC, in the retina of diabetic mice.' (Cheng L et al., 2009).
Transgenic Model
Transgenic Model are used in the study 'Heterogeneity in the sn-1 carbon chain of platelet-activating factor glycerophospholipids determines pro- or anti-apoptotic signaling in primary neurons.' (Ryan SD et al., 2008).
Related references are published most in these journals:
| Model | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
NCBI Entrez Crosslinks
All references with Platelet activating factor
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Takada Y et al. | Improvement of allograft viability with organs procured from non-heart-beating donors in porcine liver transplantation. | 2000 | Transplant. Proc. | pmid:10715416 |
| Fukuoka T et al. | Platelet activating factor mediates systemic circulatory collapse after temporary hepatic inflow occlusion. | 1993 | Transplant. Proc. | pmid:8470175 |
| Peyman JA et al. | HLA-DR genes are silenced in human trophoblasts and stimulation of signal transduction pathways does not circumvent interferon-gamma unresponsiveness. | 1992 | Transplant. Proc. | pmid:1533073 |
| Coughlan AF et al. | In vivo studies of P-selectin and platelet activating factor during endotoxemia, accelerated allograft rejection, and discordant xenograft rejection. | 1993 | Transplant. Proc. | pmid:7692651 |
| Takada Y et al. | Energy metabolism of hepatic allografts subjected to prolonged warm ischemia and pharmacologic modulation with FK506 and platelet activating factor antagonist. | 1998 | Transplant. Proc. | pmid:9838621 |
| Fukunaga K et al. | Successful liver transplantation from non-heart-beating donors by blockade of endothelin and PAE. | 1998 | Transplant. Proc. | pmid:9838664 |
| Castellvi J et al. | Effect of the platelet-activating factor antagonist BN-52021 on liver preservation (4 degrees): experimental study in isolated reperfused rat liver model. | 2002 | Transplant. Proc. | pmid:11959181 |
| Keskinoglu A et al. | Inflammatory lipid mediators and immunologic recognition in allogeneic renal transplantation. | 1997 Feb-Mar | Transplant. Proc. | pmid:9122948 |
| Kecskemeti V and Balogh I | Cardiac electrophysiologic and ultrastructural effects of platelet-activating factor and its antagonist BN 52021. | 1995 | Transplant. Proc. | pmid:7482928 |
| Yin M et al. | Platelet-activating factor antagonist TCV-309 protects rat kidneys against ischemia-reperfusion injury. | 1995 | Transplant. Proc. | pmid:7482939 |
| Spiegel HU et al. | Beneficial effect of the platelet-activating factor antagonist WEB 2170 on reperfusion injury after orthotopic liver transplantation. | 1995 | Transplant. Proc. | pmid:7482955 |
| Borobia FG et al. | Platelet-activating factor antagonist BN52021 improves survival in normothermic liver ischemia in rats. | 1993 | Transplant. Proc. | pmid:8356661 |
| Iwamoto H et al. | Beneficial effect of machine perfusion preservation on liver transplantation from non-heart-beating donors. | 2000 | Transplant. Proc. | pmid:11119873 |
| Da Costa M et al. | Prolongation of rat heart allograft survival using low-dose cyclosporine and PAF antagonist WEB 2170. | 1990 | Transplant. Proc. | pmid:2389490 |
| Bergmann R et al. | Effects of a PAF-antagonist (WEB 2086) on hyperacute xenogeneic rejection in ex vivo perfused kidneys. | 1990 | Transplant. Proc. | pmid:2389511 |
| Immunomodulation: other approaches. | 1988 | Transplant. Proc. | pmid:3347955 | |
| Renkonen R et al. | Second messenger pathways in lymphocyte binding and penetration through graft vascular endothelium. | 1991 | Transplant. Proc. | pmid:1846709 |
| Pignol B et al. | Potentiation of immunosuppressive action of cyclosporine A by platelet-activating factor antagonists: an approach of the mechanism of action of these drugs in the prevention of graft rejection. | 1988 | Transplant. Proc. | pmid:3259039 |
| First International Alexis Carrel Conference on Lipid Mediators in Organ Transplantation. April 8-10, 1986, Washington, DC. | 1986 | Transplant. Proc. | pmid:3765055 | |
| Minor T et al. | Treatment of preservation/reperfusion injury by platelet-activating factor antagonism in the rat liver graft. | 1995 | Transplant. Proc. | pmid:7879086 |
| Ide S et al. | Donor administration of PAF antagonist (TCV-309) enhances lung preservation. | 1995 | Transplant. Proc. | pmid:7879103 |
| Takada Y et al. | Platelet activating factor antagonist has a protective effect on preservation/reperfusion injury of the graft in pig liver transplantation. | 1995 | Transplant. Proc. | pmid:7879169 |
| Yin M et al. | Beneficial effect of platelet-activating factor antagonist TCV-309 on renal ischemia-reperfusion injury. | 1995 | Transplant. Proc. | pmid:7879180 |
| Hirt SW et al. | Antagonisation of platelet activating factor--a new therapeutic concept for improvement of organ quality in lung preservation. | 1992 | Transpl. Int. | pmid:14621825 |
| Torras J et al. | Protective effect of the PAF antagonist BN 52021 in an experimental renal warm ischemia model. | 1993 | Transpl. Int. | pmid:8347271 |
| Räisänen A et al. | Effect of platelet-activating factor (PAF) receptor blockers on smooth muscle cell replication in vitro and allograft arteriosclerosis in vivo. | 1993 | Transpl. Int. | pmid:8216700 |
| Shukla SD et al. | Response to platelet-activating factor in human platelets stored and aged in plasma. Decrease in aggregation, phosphoinositide turnover, and receptor affinity. | 1989 Jul-Aug | Transfusion | pmid:2546298 |
| Guerrant RL et al. | Diarrhea, demography and cell signaling: lessons from microbial toxins. | 1997 | Trans. Am. Clin. Climatol. Assoc. | pmid:9108674 |
| Melo RC et al. | Intragranular vesiculotubular compartments are involved in piecemeal degranulation by activated human eosinophils. | 2005 | Traffic | pmid:16138901 |
| Gambero A et al. | Signalling pathways regulating human neutrophil migration induced by secretory phospholipases A2. | 2004 | Toxicon | pmid:15450921 |
| Teixeira CF et al. | Hyperalgesia induced by Bothrops jararaca venom in rats: role of eicosanoids and platelet activating factor (PAF). | 1994 | Toxicon | pmid:8052996 |
| Shiroma N et al. | Haemodynamic and haematologic effects of Acanthaster planci venom in dogs. | 1994 | Toxicon | pmid:7846692 |
| Havt A et al. | The renal effects of Bothrops jararacussu venom and the role of PLA(2) and PAF blockers. | 2001 | Toxicon | pmid:11600146 |
| Castro-Faria-Neto HC et al. | Pro-inflammatory activity of enterolobin: a haemolytic protein purified from seeds of the Brazilian tree Enterolobium contortisiliquum. | 1991 | Toxicon | pmid:1796477 |
| Yara A et al. | Cardiovascular effects of Acanthaster planci venom in the rat: possible involvement of PAF in its hypotensive effect. | 1992 | Toxicon | pmid:1440631 |
| Rees RS et al. | Plasma components are required for platelet activation by the toxin of Loxosceles reclusa. | 1988 | Toxicon | pmid:3245050 |
| Freire-Maia L and de Matos IM | Heparin or a PAF antagonist (BN-52021) prevents the acute pulmonary edema induced by Tityus serrulatus scorpion venom in the rat. | 1993 | Toxicon | pmid:8266352 |
| Tai H et al. | TMVA, a snake C-type lectin-like protein from Trimeresurus mucrosquamatus venom, activates platelet via GPIb. | 2004 | Toxicon | pmid:15501291 |
| Grandoni KM et al. | Trichothecene mycotoxins inhibit phosphoinositide hydrolysis in bovine platelets stimulated with platelet activating factor. | 1992 | Toxicology | pmid:1311467 |
| Pearson JM et al. | Neither platelet activating factor nor leukotrienes are critical mediators of liver injury after lipopolysaccharide administration. | 1997 | Toxicology | pmid:9231696 |
| Flaherty MM et al. | Nonclinical evaluation of GMA161--an antihuman CD16 (FcγRIII) monoclonal antibody for treatment of autoimmune disorders in CD16 transgenic mice. | 2012 | Toxicol. Sci. | pmid:22025730 |
| Feuerstein G et al. | Protective effect of a PAF-acether antagonist, BN 52021, in trichothecene toxicosis. | 1987 | Toxicol. Lett. | pmid:3660430 |
| Bailie MB et al. | Platelet activating factor receptor blockade alone or in combination with leukotriene synthesis inhibition does not ameliorate alpha-naphthylisothiocyanate-induced hepatotoxicity. | 1996 | Toxicol. Lett. | pmid:8614909 |
| Mahgoub AA | Thymoquinone protects against experimental colitis in rats. | 2003 | Toxicol. Lett. | pmid:12749817 |
| Baskin SI et al. | The effects of EDRF/NO releasers or calcium ionophore A23187 on cyanide toxicity in mice. | 1996 | Toxicol. Appl. Pharmacol. | pmid:8806852 |
| Wright DT et al. | Ozone stimulates release of platelet activating factor and activates phospholipases in guinea pig tracheal epithelial cells in primary culture. | 1994 | Toxicol. Appl. Pharmacol. | pmid:8048050 |
| Nomura DK et al. | Dual roles of brain serine hydrolase KIAA1363 in ether lipid metabolism and organophosphate detoxification. | 2008 | Toxicol. Appl. Pharmacol. | pmid:18164358 |
| Samet JM and Friedman M | Effect of ozone on platelet activating factor metabolism in phorbol-differentiated HL60 cells. | 1992 | Toxicol. Appl. Pharmacol. | pmid:1440609 |
| Hanslik T et al. | Effect of the platelet activating factor antagonist BN52021 in rabbits: role in gentamicin nephrotoxicity. | 1994 | Toxicol. Appl. Pharmacol. | pmid:8079343 |
| Ramos G et al. | Platelet activating factor receptor binding plays a critical role in jet fuel-induced immune suppression. | 2004 | Toxicol. Appl. Pharmacol. | pmid:15020195 |